The Life Sciences Virtual Investor Forum, scheduled for March 11 and 12, 2026, represents a significant opportunity for public companies across therapeutic and healthcare markets to connect with a global audience of individual and institutional investors. As a B2i Digital Featured Conference co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, this virtual event leverages digital platforms to bridge the gap between corporate management and the investment community.
The forum's structure enables presenting companies to deliver scheduled live presentations followed by real-time question-and-answer sessions, providing investors with immediate access to executive insights. Beyond the scheduled presentations, investors can request one-on-one meetings with management teams through the VIC platform, creating opportunities for deeper dialogue about company strategies, therapeutic pipelines, and market positioning. This interactive format addresses a critical need in the life sciences sector, where complex scientific developments require direct communication between companies and potential investors.
B2i Digital serves as the Official Marketing Partner for the event, supporting awareness through digital marketing, social media promotion, and comprehensive digital profiles of presenting companies. This marketing partnership extends the reach of participating companies beyond traditional investor relations channels, potentially increasing visibility among the proprietary network of more than 1.5 million market participants that B2i Digital maintains. For detailed information about the forum, interested parties can visit https://b2idigital.com/otc-life-sciences-virtual-investor-forum.
The presenting company roster includes SeaStar Medical Holding Corporation, Nasus Pharma Ltd., Tonix Pharmaceuticals Holding Corp., and Jupiter Neurosciences, Inc. on March 11, followed by Bora Pharmaceuticals, Prostatype Genomics AB, MetaVia Inc., Phio Pharmaceuticals Corp., Avicanna Inc., EMVision Medical Devices Ltd., Aethlon Medical, Dyadic International, Jaguar Health, Inc., Beyond Air, Inc., Cadrenal Therapeutics, Inc., and Amplia Therapeutics Ltd. on March 12. Among these presenters, Jupiter Neurosciences, Inc. and Phio Pharmaceuticals Corp. are designated as B2i Digital Featured Companies, indicating additional marketing support through B2i Digital's programs.
Virtual Investor Conferences, an OTC Markets Group Inc. property, provides the technological platform for this investor engagement, with participating companies representing multiple exchanges including NYSE, Nasdaq, TSX, CSE, ASX, and OTC Markets. The availability of presentation replays for on-demand viewing after the live event extends the visibility window for participating companies, allowing investors who cannot attend live sessions to access the content at their convenience. For comprehensive profiles of all participating companies and registration details, the event page at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/147666/march-12th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC serves as the primary resource.
The implications of this investor forum extend beyond the immediate presentations. For the life sciences industry, such virtual events democratize access to investment opportunities by removing geographical barriers that traditionally limited investor-company interactions. Smaller public companies, particularly those in specialized therapeutic areas, benefit from increased visibility among both retail and institutional investors who might otherwise overlook them in crowded markets. The interactive format also allows investors to assess management teams directly, an important factor in life sciences investing where leadership experience and communication effectiveness can significantly influence investment decisions.
For the broader investment community, virtual investor conferences represent an evolution in how market participants discover and evaluate public companies. The efficiency of accessing multiple management teams in a condensed timeframe, combined with the ability to request targeted one-on-one meetings, creates a more streamlined due diligence process. As digital platforms continue to transform capital markets engagement, events like the Life Sciences Virtual Investor Forum demonstrate how technology can enhance transparency and accessibility in public company-investor communications.
